Drug Trial Radar · NCT03344458
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
298
Actual
Start
Dec 19, 2017
Primary completion
Feb 21, 2023
Study completion Feb 21, 2023
Sponsor
- Lead sponsor
- Ascendis Pharma A/SIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial. Approximately 300 children (males and females) with GHD will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Poland, Bulgaria, Ukraine, Armenia, Russia and Australia.
Conditions
- Growth Hormone Deficiency, Pediatric
- Endocrine System Diseases
- Hormone Deficiency
- Pituitary Diseases
Interventions
TransCon hGHDrug
Once weekly subcutaneous injection of TransCon hGH
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Treatment-Emergent Adverse Events [Long-Term Safety and Tolerability]Time frame: Up to Week 208
Locations
42 sites in 11 countries. Site status is shown where the registry gives one.
Ascendis Pharma Investigational Site
Birmingham, Alabama
Ascendis Pharma Investigational Site
Los Angeles, California
Ascendis Pharma Investigational Site
Orange, California
Ascendis Pharma Investigational Site
Sacramento, California
Ascendis Pharma Investigational Site
Centennial, Colorado
Ascendis Pharma Investigational Site
Jacksonville, Florida
Ascendis Pharma Investigational Site
Orlando, Florida
Ascendis Pharma Investigational Site
Tallahassee, Florida
Ascendis Pharma Investigational Site
Saint Paul, Minnesota
Ascendis Pharma Investigational Site
Jackson, Mississippi
Ascendis Pharma Investigational Site
Lebanon, New Hampshire
Ascendis Pharma Investigational Site
Mineola, New York
Ascendis Pharma Investigational Site
New York, New York
Ascendis Pharma Investigational Site
Cleveland, Ohio
Ascendis Pharma Investigational Site
Oklahoma City, Oklahoma
Ascendis Pharma Investigational Site
Portland, Oregon
Ascendis Pharma Investigational Site
Portland, Oregon
Ascendis Pharma Investigational Site
Dallas, Texas
Ascendis Pharma Investigational Site
Fort Worth, Texas
Ascendis Pharma Investigational Site
Charlottesville, Virginia
Ascendis Pharma Investigational Site
Norfolk, Virginia
Ascendis Pharma Investigational Site
Tacoma, Washington
Ascendis Pharma Investigational Site
Yerevan, Armenia
Ascendis Pharma Investigational Site
Clayton, Victoria, Australia
Ascendis Pharma Investigational Site
Minsk, Belarus
Ascendis Pharma Investigational Site
Varna, Bulgaria
Ascendis Pharma Investigational Site
Tbilisi, Georgia
Ascendis Pharma Investigational Site
Athens, Greece
Ascendis Pharma Investigational Site
Auckland, New Zealand
Ascendis Pharma Investigational Site
Gdansk, Poland
Ascendis Pharma Investigational Site
Warsaw, Poland
Ascendis Pharma Investigational Site
Izhevsk, Russia
Ascendis Pharma Investigational Site
Krasnoyarsk, Russia
Ascendis Pharma Investigational Site
Moscow, Russia
Ascendis Pharma Investigational Site
Saint Petersburg, Russia
Ascendis Pharma Investigational Site
Saratov, Russia
Ascendis Pharma Investigational Site
Ufa, Russia
Ascendis Pharma Investigational Site
Vologda, Russia
Ascendis Pharma Investigational Site
Voronezh, Russia
Ascendis Pharma Investigational Site
Kharkiv, Ukraine
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.